新股消息 | 天辰生物医药再度递表港交所

Group 1 - Tianchen Biopharma (Suzhou) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1] - The company focuses on the discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases, with a core product LP-003, an anti-IgE antibody [1] - LP-003 aims to block free IgE in blood and tissues to inhibit IgE-mediated allergic reactions, targeting conditions such as allergic rhinitis, chronic spontaneous urticaria, and allergic asthma [1]